Robert Richard Ruffolo

Dr. Robert Richard Ruffolo is an Independent Director at LB Pharmaceuticals, Inc., a Non-Executive Independent Director at Aragen Life Sciences Ltd., an Independent Director at Elicio Therapeutics, Inc., an Independent Director at Elicio Therapeutics, Inc. (United States), a Managing Director at Ruffolo Consulting LLC and a President at Wyeth Research.
He is on the Board of Directors at Combined Therapeutics, Inc., Neuraptive Therapeutics, Inc., Nacuity Pharmaceuticals, Inc., Ocuterra Therapeutics, Inc., LB Pharmaceuticals, Inc., Aragen Life Sciences Ltd., Elicio Therapeutics, Inc., Elicio Therapeutics, Inc. (United States), Biotechnology Innovation Organization, Elucida Oncology, Inc., eXIthera Pharmaceuticals, Inc. and Sapience Therapeutics, Inc. Dr. Ruffolo was previously employed as an Independent Director by Diffusion Pharmaceuticals, Inc., an Independent Director by Aridis Pharmaceuticals, Inc., an Independent Director by Sigilon Therapeutics, Inc., a Senior Vice President by Wyeth LLC, a President-Research & Development, Senior VP by Wyeth Pharmaceuticals LLC, and a Senior VP & Director-Biological Sciences by GlaxoSmithKline Plc.
He also served on the board at Trevena, Inc., Lipidio Pharmaceuticals, Inc. and The West Virginia University Foundation, Inc. He received his undergraduate degree from The Ohio State University and a doctorate degree from The Ohio State University.